

Number of Metabolic Syndrome Risk Factors is Related to Carotid Intima-Media Thickness in Rheumatoid Arthritis Patients

Ferhat GÖKMEN,¹ Ahmet TEMİZ,² Ayla AKBAL,¹ Hacer ŞEN,³ Coşkun ZATERİ,¹ Esra GÖKMEN,⁴
Emre BOZKURT,¹ Hatice REŞORLU,¹ Tolga KURT,⁵ Yılmaz SAVAŞ¹

¹Department of Physical Medicine and Rehabilitation, Medical Faculty of Çanakkale Onsekiz Mart University, Çanakkale, Turkey

²Department of Cardiology, Medical Faculty of Çanakkale Onsekiz Mart University, Çanakkale, Turkey

³Department of Internal Medicine, Medical Faculty of Çanakkale Onsekiz Mart University, Çanakkale, Turkey

⁴Department of Internal Medicine, Çanakkale State Hospital, Çanakkale, Turkey

⁵Department of Cardiovascular Surgery, Medical Faculty of Çanakkale Onsekiz Mart University, Çanakkale, Turkey

ABSTRACT

Objectives: This study aims to investigate the relationship between carotid intima-media thickness (CIMT) and clinical and metabolic variables in rheumatoid arthritis (RA) patients.

Patients and methods: The study included 76 RA patients (18 males, 58 females; mean age 50.1±9.8 years; range 21 to 69 years) and 42 control subjects (11 males, 31 females; mean age 49.2±9.7; range 28 to 66 years). Erythrocyte sedimentation rate, C-reactive protein, and disease activity score were used to assess disease activation. Rheumatoid factor, anti-cyclic citrullinated peptide antibodies, and metabolic syndrome components (fasting blood glucose, high density lipoprotein-cholesterol, triglyceride, blood pressure, and waist circumference) were measured.

Results: Mean disease duration was 6.9±6.5 years. Patients with RA had higher CIMT than the controls (0.8±0.1 and 0.6±0.2, respectively; p<0.001). Statistically significant positive correlations were observed between CIMT and age, erythrocyte sedimentation rate, C-reactive protein, and systolic and diastolic blood pressure. The CIMT in RA patients having metabolic syndrome risk components ranging from one to four were 0.76±0.16, 0.82±0.14, 0.86±0.13, and 0.92±0.13, respectively. CIMT was positively correlated with the number of metabolic syndrome risk components.

Conclusion: Our study has shown elevated CIMT in RA. Presence of metabolic syndrome components in RA patients increases tendency to atherosclerosis and constitutes a severe risk for cardiovascular disease.

Keywords: Cardiovascular risk; carotid intima media thickness; metabolic syndrome risk factors; rheumatoid arthritis.

Rheumatoid arthritis (RA) is a systemic inflammatory disease which causes increased risk of cardiovascular disease (CVD), and is characterized by chronic erosive synovitis of the peripheral joints. Important factors in the increased risk of CVD in RA patients are chronic inflammation, drugs used in treatment of RA, and a sedentary lifestyle.¹ Chronic inflammation is the most important reason for accelerated atherosclerosis development in RA.² Cytokines involved in the systemic circulation in RA have altered function in distant organs such as adipose tissue, liver, and skeletal muscle. Thus, they

cause a series of atherogenic changes such as insulin resistance, dyslipidemia, oxidative stress, thrombotic effects, endothelial dysfunction, and injury. Even during remission periods of the disease, systemic cytokine levels were found to be higher than those of normal individuals and they caused continued vascular disease.³

In various studies, increased carotid intima-media thickness (CIMT) has been shown to be a good indicator of atherosclerosis. CIMT has been reported to correlate with myocardial infarction, stroke, and peripheral artery disease.⁴⁻⁷ Not only is increased CIMT indicative of early atherosclerosis,

Received: July 18, 2014 **Accepted:** September 15, 2014 **Published online:** February 13, 2015

Correspondence: Ferhat Gökmen, M.D. Çanakkale Onsekiz Mart Üniversitesi Tıp Fakültesi Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı, 17020 Çanakkale, Turkey.

Tel: +90 286 - 263 59 50 e-mail: ferhatgokmen06@hotmail.com

©2015 Turkish League Against Rheumatism. All rights reserved.

but it also reflects the compensatory enlargement of non-atherosclerotic tissue with thickened medial fibrocellular hypertrophy related to smooth muscle cell hyperplasia and hypertrophy.^{4,8} Increased CIMT and the presence of focal plaque in patients with RA not having traditional CVD risk factors may be a harbinger of cardiovascular events.^{9,10} In the conducted studies, a strong correlation has been shown between the presence of subclinical atherosclerosis and the duration and severity of inflammation and the level of acute phase reactants.¹

Metabolic syndrome (MetS) is a disorder characterized by a co-occurrence of three out of five of the following medical conditions: abdominal obesity, elevated blood pressure, high serum triglycerides, low high-density cholesterol levels, and elevated fasting plasma glucose.¹¹ Some studies showed that increased numbers of MetS risk components lead to worsening cardiovascular disease outcomes and risk factors.¹² Although CIMT is related to metabolic parameters, only a few studies have investigated the relationship between numbers of MetS risk parameters and CIMT.¹² Therefore, in this study, we aimed to investigate the relationship between CIMT and clinical and metabolic variables in RA patients.

PATIENTS AND METHODS

This study was carried out at the Canakkale Onsekiz Mart University Medical Faculty Hospital between April 2012 and January 2013. A total of 118 subjects including 76 RA patients (18 males, 58 females; mean age 50.1 ± 9.8 years; range 21 to 69 years) and 42 healthy individuals (11 males, 31 females; mean age 49.2 ± 9.7 ; range 28 to 66 years) were enrolled. All patients gave informed consent forms and the study was approved by the local ethical committee.

Patients were asked about their age, sex, height, weight, body mass index, waist circumference, systolic and diastolic blood pressure, duration of illness, smoking and alcohol consumption status, presence of accompanying chronic diseases, morning stiffness in the joints and duration, and the drugs they continued to use. Laboratory and clinical parameters such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Health Assessment Questionnaire

score, and Disease activity score 28 were used in assessing disease activation. Pain evaluation was done using a visual analog scale with a range from 0 to 100 mm. Rheumatoid factor and anti-cyclic citrullinated peptide were measured. MetS was defined according to the National Education Program/Adult Treatment Panel III criteria and MetS components [glucose higher than 110 mg/dL, high-density cholesterol less than 40 mg/dL (males) or less than 50 mg/dL (females), triglycerides higher than 150 mg/dL, blood pressure higher than 130/80 mmHg or medication for hypertension and waist circumference of 88 cm for females or 102 cm for males] were measured.¹¹ Exclusion criteria consisted of age ≤ 18 years, chronic liver/kidney disease, central nervous system disease, malignancy, patients with other inflammatory diseases, and patients who refused to participate in the study.

Echocardiographic measurements with a linear-array imaging probe (GE-vingmed Vivid 7, GE Vingmed Ultrasound AS, Horten, Norway) were employed to evaluate the CIMT of the right common carotid artery. A region 10 mm proximal to the carotid bifurcation was identified, and the CIMT of the far wall was calculated as the distance between the lumen-intima and media-adventitia interfaces. A frozen image distinctly indicating the borders of the intima and media was obtained and magnified to maximize resolution. CIMT was measured on this image at three adjacent sites 1 mm apart, and the mean value of the three measurements was used for analyses. All measurements were performed by the same investigator, who was blinded to all patient data.

Statistical analysis

Analysis of data was performed with SPSS version 15.0 software program (SPSS Inc., Chicago, IL, USA). Normal distribution of data was examined using the Kolmogorov-Smirnov and Shapiro-Wilk tests. Descriptive variables were expressed as mean, standard deviation, median, minimum, maximum, frequency, and percentage values. Variables normally distributed between groups were analyzed using the Student's *t* test and non-normally distributed variables using the Mann-Whitney *U* test. The Chi-square test was used for categorical variables. Correlation between

Table 1. Comparison of demographic and clinical parameters of groups

Variables	Patient (n=76)			Control (n=42)		p
	n	%	Mean±SD	%	Mean±SD	
Age (years)			50.1±9.8		49.2±9.7	0.642
Female		76.3	–	73.8	–	0.762
Body mass index (kg/m ²)			29.2±5.4		28.3±5.4	0.378
Waist circumference (cm)			95.2±9.9		93.7±6.6	0.379
Systolic blood pressure (mmHg)			131.3±24.8		120.4±16.8	0.013
Diastolic blood pressure (mmHg)			79.4±13.0		75.8±8.5	0.106
Fasting blood glucose (mg/dL)			91.1±18.4		96.2±12.9	0.087
Triglyceride (mg/dL)			108.8±50.1		117.7±62.7	0.405
High-density lipoprotein cholesterol (mg/dL)			58.6±17.6		57.4±14.1	0.698
Carotid intima-media thickness (mm)			0.81±0.14		0.61±0.15	<0.001
Erythrocyte sedimentation rate (mm/hour)			39.2±20.1		22.7±17.2	<0.001
C-reactive protein (mg/dL)			2.0±2.4		0.6±0.5	<0.001
Rheumatoid factor positivity	55	72.4	–		–	–
Anti-CCP positivity	53	69.7	–		–	–
Disease activity score 28			4.0±1.3		–	–
Health assessment questionnaire			0.71±0.61		–	–
Visual analog scale (mm)			36±24		–	–

SD: Standard deviation.

variables in the patient group was analyzed using Spearman's correlation test. $P<0.05$ was regarded as statistically significant.

RESULTS

Mean disease duration of RA patients was 6.9 ± 6.5 years. Demographic and clinical parameters of the subjects are given in Table 1. Patients with RA had higher systolic blood pressure, CIMT (Figure 1), ESR, and CRP values than those of the control subjects ($p=0.013$, $p<0.001$, $p<0.001$, $p<0.001$, respectively).

A correlation analysis of the relationship between CIMT and clinical parameters (Table 2) revealed significant correlations between CIMT and age ($r=0.381$, $p<0.001$), ESR ($r=0.297$, $p=0.001$), CRP ($r=0.429$, $p<0.001$), systolic ($r=0.353$, $p<0.001$) and diastolic blood pressure ($r=0.294$, $p=0.001$). MetS frequency was detected in 25 RA patients (32.9%) and 11 control subjects (26.2%) ($p=0.449$). We evaluated the relationship between the number of MetS components and CIMT only in RA patients. We observed that CIMT increased when the number of MetS components increased. The CIMT in RA patients having MetS components ranging from one to four were 0.76 ± 0.16 , 0.82 ± 0.14 , 0.86 ± 0.13 , and 0.92 ± 0.13 ,

respectively ($p=0.13$). We demonstrated that CIMT was positively correlated with the number of MetS components ($p=0.018$, $r=0.271$). CIMT according to the number of MetS components in patients with RA is shown in Figure 2.

DISCUSSION

In the present study, we detected higher CIMT in patients with RA. Additionally, there was a




Figure 1. Carotid intima-media thickness values in rheumatoid arthritis and control groups.


Table 2. Correlations between carotid intima-media thickness and clinical and laboratory values

	CIMT	
	r	p
Age (year)	0.381	<0.001
Waist circumference (cm)	0.168	0.069
Systolic blood pressure (mmHg)	0.353	<0.001
Diastolic blood pressure (mmHg)	0.294	0.001
Fasting blood glucose (mg/dL)	-0.015	0.871
Triglyceride (mg/dL)	0.041	0.658
High-density lipoprotein cholesterol (mg/dL)	-0.087	0.354
Erythrocyte sedimentation rate (mm/hour)	0.297	0.001
C-reactive protein (mg/dL)	0.429	<0.001
Disease activity score 28	0.078	0.501
Health assessment questionnaire	0.077	0.509

CIMT: Carotid intima-media thickness.

positive correlation between CIMT and both ESR and CRP. The study also showed that CIMT gradually increased with the number of MetS components from one to four and there was a positive correlation between CIMT and risk number for MetS.

The incidence of CVD in RA patients is independent of traditional cardiovascular risk factors.¹³ Cardiovascular mortality has been correlated with greater activity of the disease. The inflammation that occurs in persons with RA has been suggested to accelerate the atherosclerotic process. Measurement of CIMT is a useful noninvasive marker of atherosclerotic disease. Previous studies demonstrated that increased common CIMT is a good indicator of generalized atherosclerosis and coronary artery disease.¹⁴ CIMT has been related to several cardiovascular risk factors, including obesity, hyperlipidemia, and type 2 diabetes mellitus and insulin resistance. Studies have previously reported the presence of subclinical atherosclerosis, confirmed by increased CIMT, in RA patients without a clinical history of cardiovascular events.^{15,16} In the study of Del Rincón et al.,¹⁷ authors showed increased CIMT in patients with RA and a relationship with disease duration. We have shown that disease duration is not related to CIMT. This result may be explained by the short duration of disease. Previous studies showed not only disease duration to be an important risk factor, but also inflammation severity, CRP level, and number of joints involved as significant factors for elevated CIMT. Therefore, we might not have found a

**Figure 2.** Carotid intima-media thickness values according to number of MetS components in patients with rheumatoid arthritis.

link between CIMT and disease duration due to other factors. However, in our study, CIMT was higher in RA patients than in the control group, demonstrating the presence of subclinical atherosclerosis in RA patients, and corroborating the findings of a majority of the previous work in this field.

The association between carotid atherosclerosis and inflammatory markers such as ESR and CRP has been shown to be independent of cardiovascular risk factors.¹⁸ A strong correlation was identified between the presence of subclinical atherosclerosis and the magnitude and duration of the inflammatory response obtained by evaluating CRP levels in RA patients.¹⁹ In our study, we have detected a weak correlation between CIMT and ESR and CRP as clinical parameters indicating inflammation. This is a significant result regarding the inflammatory response correlating with the atherosclerotic process and cardiovascular mortality.

The relationship between CIMT and metabolic parameters in RA patients has been widely investigated. Also, a close relationship between CIMT and a number of cardiovascular risk factors has been demonstrated.²⁰ The presence of metabolic parameters such as hypertension, diabetes, and hyperlipidemia in patients with RA causes an increased risk of CVD, and markers of disease severity together with metabolic

parameters are stated to contribute to predicting the risk of developing CVD.²¹ In another study, a significant relationship was found between CIMT and hypertension and abdominal circumference.²² In our study, we showed a correlation between CIMT and systolic and diastolic blood pressure from among metabolic parameters in RA patients. These results, when evaluated together with those of other studies, indicate that these metabolic parameters in RA patients are associated with increased CIMT, giving an increased risk of cardiovascular morbidity and mortality. Another important finding from our study was that CIMT was correlated with the number of MetS parameters in RA patients. We detected that CIMT gradually increased with the number of MetS parameters increasing from one to four. Therefore, we hypothesize that CIMT may be related to cardiovascular mortality.

In conclusion, our study has shown elevated CIMT values in RA. We also demonstrated that CIMT correlated with hypertension from among other metabolic parameters. The results of this study suggest that the number of components of MetS present in patients with RA increases the tendency to atherosclerosis, thus constituting a risk for CVD.

Declaration of conflicting interests

The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Funding

The authors received no financial support for the research and/or authorship of this article.

REFERENCES

1. del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. *Arthritis Rheum* 2001;44:2737-45.
2. Stamatelopoulos KS, Kitas GD, Papamichael CM, Chrysoshoou E, Kyrkou K, Georgiopoulos G, et al. Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. *Arterioscler Thromb Vasc Biol* 2009;29:1702-8.
3. Turesson C, Jacobsson L, Bergström U. Extra-articular rheumatoid arthritis: prevalence and mortality. *Rheumatology (Oxford)* 1999;38:668-74.
4. Kuller L, Borhani N, Furberg C, Gardin J, Manolio T, O'Leary D, et al. Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study. *Am J Epidemiol* 1994;139:1164-79.
5. Touboul PJ, Elbaz A, Koller C, Lucas C, Adraï V, Chédru F, et al. Common carotid artery intima-media thickness and brain infarction : the Etude du Profil Génétique de l'Infarctus Cérébral (GENIC) case-control study. The GENIC Investigators. *Circulation* 2000;102:313-8.
6. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. *N Engl J Med* 1999;340:14-22.
7. Poredos P. Intima-media thickness: indicator of cardiovascular risk and measure of the extent of atherosclerosis. *Vasc Med* 2004;9:46-54.
8. Homma S, Hirose N, Ishida H, Ishii T, Araki G. Carotid plaque and intima-media thickness assessed by b-mode ultrasonography in subjects ranging from young adults to centenarians. *Stroke* 2001;32:830-5.
9. Gonzalez-Juanatey C, Llorca J, Martin J, Gonzalez-Gay MA. Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. *Semin Arthritis Rheum* 2009;38:366-71.
10. Evans MR, Escalante A, Battafarano DF, Freeman GL, O'Leary DH, del Rincón I. Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis. *Arthritis Rheum* 2011;63:1211-20.
11. Gonzalez-Gay MA, Gonzalez-Juanatey C, Piñeiro A, Garcia-Porrua C, Testa A, Llorca J. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. *J Rheumatol* 2005;32:1219-23.
12. Sirdah MM, Abu Ghali AS, Al Laham NA. The reliability of the National Cholesterol Education Program's Adult Treatment Panel III (NCEP/ATP III) and the International Diabetes Federation (IDF) definitions in diagnosing metabolic syndrome (MetS) among Gaza Strip Palestinians. *Diabetes Metab Syndr* 2012;6:4-8.
13. Gunes F, Akbal E, Asik M, Sen H, Binnetoglu E, Kizilgun M, et al. Number of metabolic syndrome risk parameters associated with TAFIa/ai antigen levels. *Blood Coagul Fibrinolysis* 2013;24:844-7.
14. del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. *Arthritis Rheum* 2001;44:2737-45.
15. Simons PC, Algra A, Bots ML, Grobbee DE, van der Graaf Y. Common carotid intima-media thickness and arterial stiffness: indicators of cardiovascular risk in high-risk patients. The SMART Study (Second

- Manifestations of ARterial disease). *Circulation* 1999;100:951-7.
16. Gonzalez-Juanatey C, Llorca J, Testa A, Revuelta J, Garcia-Porrúa C, Gonzalez-Gay MA. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. *Medicine (Baltimore)* 2003;82:407-13.
 17. Turkyilmaz AK, Devrimsel G, Kirbas A, Cicek Y, Karkucak M, Capkin E, et al. Relationship between pulse wave velocity and serum YKL-40 level in patients with early rheumatoid arthritis. *Rheumatol Int* 2013;33:2751-6.
 18. Del Rincón I, O'Leary DH, Freeman GL, Escalante A. Acceleration of atherosclerosis during the course of rheumatoid arthritis. *Atherosclerosis* 2007;195:354-60.
 19. Park YB, Ahn CW, Choi HK, Lee SH, In BH, Lee HC, et al. Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. *Arthritis Rheum* 2002;46:1714-9.
 20. Salonen R, Tervahauta M, Salonen JT, Pekkanen J, Nissinen A, Karvonen MJ. Ultrasonographic manifestations of common carotid atherosclerosis in elderly eastern Finnish men. Prevalence and associations with cardiovascular diseases and risk factors. *Arterioscler Thromb* 1994;14:1631-40.
 21. Solomon DH, Kremer J, Curtis JR, Hochberg MC, Reed G, Tsao P, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. *Ann Rheum Dis* 2010;69:1920-5.
 22. Galarza-Delgado DA, Esquivel-Valerio JA, Garza-Elizondo MA, Góngora-Rivera F, Muñoz-De Hoyos JL, Serna-Peña G. Carotid atherosclerosis in patients with rheumatoid arthritis and rheumatoid nodules. *Reumatol Clin* 2013;9:136-41.